<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 14-year-old boy has undergone kidney transplantation due to stage V chronic kidney disease. A pre-transplantation serologic assessment showed that he is negative for past or present HIV infection, viral hepatitis, EBV, and CMV infection. He has a known allergy for macrolides. The patient has no complaints 1 day after transplantation. His vital signs include: blood pressure 12070 mm Hg, heart rate 89min, respiratory rate 17min, and temperature 37.0C 98.6F. On physical examination, the patient appears to be pale, his lungs are clear on auscultation, heart sounds are normal, and his abdomen is non-tender on palpation. His creatinine is 0.65 mgdL 57.5 μmolL, GFR is 71.3 mLmin1.73 m2, and urine output is 0.9 mLkgh. Which of the following drugs should be used in the immunosuppressive regimen in this patient?? A: Sirolimus, B: Basiliximab, C: Daclizumab, D: Belatacept, E: Omalizumab,  <response>: This is a question about choosing an appropriate immunosuppressive drug regimen for a 14-year-old boy who has undergone kidney transplantation. The key details in the stem are: - He has undergone kidney transplantation for stage V chronic kidney disease- Pre-transplant serology showed he is negative for HIV, hepatitis, EBV, and CMV - He has a known allergy to macrolides- 1 day post-transplant he is clinically stable with good graft functionThe choices given are different immunosuppressive agents. Since he is EBV and CMV negative, basiliximab or daclizumab anti-IL-2 receptor antibodies would be reasonable choices to induce immunosuppression and prevent acute rejection. Sirolimus is also a possibility as maintenance immunosuppression, but carries risks of wound healing problems and fluid retention early post-transplant. Belatacept is not used in pediatric transplant patients. Omalizumab is an anti-IgE antibody and not relevant for this scenario.B: Basiliximab 